A modified melanoma-molGPA scoring model: assessment of survival after and efficacy of different radiotherapy modalities in patients with melanoma brain metastases.

ABSTRACT:

Purpose

Patients with malignant melanoma brain metastases (MBMs) have poor prognoses. For MBMs, the Melanoma-molGPA is the most widely used predictive score, but its predictive value remains uncertain in patients fully treated with radiotherapy. We identified MBMs prognostic factors and modified the prognostic scoring model.

Methods

We retrospectively analyzed patients diagnosed with MBMs between December 2010 and November 2021 for prognostic factors influencing overall survival (OS) by univariate and multivariate analyses. Nomogram plots were based on Cox regression modeling. We evaluated overall survival (OS) using Kaplan-Meier survival curves and log-rank tests.

Results

The median OS (mOS) was 7.9 months. On multivariate analysis, BRAF mutation status (p < 0.001),

SUBMITTER: Wu Q 

PROVIDER: S-EPMC10310639 | biostudies-literature | 2023 Jun

REPOSITORIES: biostudies-literature